deltatrials
Completed PHASE1 NCT03005782

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies

Sponsor: Regeneron Pharmaceuticals

Conditions Malignancies
Interventions REGN3767 cemiplimab
Updated 21 times since 2017 Last updated: Apr 29, 2024 Started: Nov 7, 2016 Primary completion: Apr 2, 2024 Completion: Apr 2, 2024

A PHASE1 clinical study on Malignancies, this trial is completed. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 21 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2019 · 13 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~May 2020 · 4 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~May 2022 · 8 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Dec 2023 · 15 months · monthly snapshot~Dec 2023 – ~Jun 2024 · 6 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Dec 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 16 earlier versions

  1. Sep 2022 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  3. Sep 2021 — May 2022 [monthly]

    Recruiting PHASE1

  4. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  5. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  6. May 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  7. Jan 2020 — May 2020 [monthly]

    Recruiting PHASE1

  8. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  9. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  10. Aug 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  11. Jul 2018 — Aug 2019 [monthly]

    Recruiting PHASE1

  12. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  13. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  14. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE1

  15. Feb 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Regeneron Pharmaceuticals
Data source: Regeneron Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Atlanta, United States , Aurora, United States , Brisbane, Australia , Buffalo, United States , Charleston, United States , Charlotte, United States , Cleveland, United States , Detroit, United States , Dublin, Ireland and 28 more locations